Aakash Babu has covered the pharmaceutical sector since 2018, starting his career at Reuters, where he specialised in tackling company news. Just before joining the Citeline team, he worked as a healthcare analyst at the Economist Group, focusing on disease trends, drug development, regulatory changes and pharmaceutical pricing. He has a master’s in economics and a post-graduate specialisation in business journalism from Asian College of Journalism-Bloomberg. He was a key member of the team that covered the initial breakthroughs in COVID-19 vaccine research during his time at Reuters. He also has experience in forecasting regulatory trends, drug approvals and pharmaceutical sales. Outside of work he enjoys traveling, writing and watching football.
Latest from Aakash Babu
Joshi joins the parent company of Citeline, home of HBW Insight, to focus on AI, business harmonization and long-term growth.
Joshi joins the parent company of Citeline, home of the Pink Sheet, to focus on AI, business harmonization and long-term growth.
Joshi joins the parent company of Citeline, home of Medtech Insight, to focus on AI, business harmonization and long-term growth.
Joshi joins the parent company of Citeline, which houses flagship publications Generics Bulletin, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.
Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.
Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.